- Senior Leadership
- Leadership Tübingen
- Leadership Houston
- Leadership Munich
Associate Director Business Development
Ajla Hrle joined Immatics’ Business Development team in February of 2016. Her responsibilities include search and evaluation as well as transaction-related aspects of building strategic partnerships and value enhancing collaborations. Starting in 2017 Ajla re-launched Immatics’ external Corporate Communications with a goal of enhancing Immatics’ social eminence and broader presence.
Prior to joining Immatics Ajla led business development in Scandinavian markets for Nanotemper Technologies where she applied her knowledge and expertise in biophysics and protein biochemistry.
Ajla received her Diploma in Biochemistry from the University of Tübingen and performed her PhD studies at the Max Planck Institute for Biochemistry in Martinsried as a fellow of the Schering foundation, focusing on structurally and functionality characterizing CRISPR proteins.
Vice President CMC
Ali Mohamed joined Immatics in May 2016 and is responsible for all aspects of process development and GMP manufacturing of Immatics T-cell products.
Previously, Ali held CMC related roles in multiple CMOs and clinical stage biotechnology companies in the field of cell & gene therapies. His previous role was at Hitachi PCT in Allendale NJ as senior director of GMP manufacturing and manufacturing development. Prior to joining Hitachi PCT, Ali held the role of director of GMP manufacturing and process development at AlloCure, a clinical stage company developing cell-based therapies for acute kidney injury. Prior to that Ali was the senior management of process development at Lonza in Walkersville, MD helping various cell therapy companies with developing cell-based products for various diseases. Ali also held scientist/senior scientist positions at a few small biotechnology companies including Neurologic (Rockville, MD), Psychiatric Genomics (Gaithersburg, MD), and Osiris Therapeutics (Baltimore, MD).
Ali Mohamed holds a PhD in Biomedical Sciences with concentration of Pharmacology from the University of Toledo (formerly Medical College of Ohio), postdoctoral training from the Georgetown Institute of Cognitive and Computation Sciences (GICCS) in Washington, DC, and Bachelor in Pharmaceutical Sciences from the Cairo University in Egypt.
Director Clinical Operations & Clinical Development
Andrea Mayer-Mokler joined Immatics in September 2005 and is responsible for Clinical Development and Clinical Operations in Europe.
Andrea has been in clinical development/operations all her professional life with increasing responsibilities. After University she joined Merck Sharp & Dohme working as Manager Clinical Research on various indications. Thereafter she moved to Igeneon and entered the field of cancer immunotherapies. 14 years ago, Andrea joined Immatics as the first Clinical Study Director being responsible for several international cancer vaccine trials and leading the cross-functional project teams. She is currently responsible for clinical development of the ACT trials which are being conducted in US and Europe and clinical operations in Europe.
Andrea Mayer-Mokler holds a PhD in Tumor biology and Oncology from the Medical University of Vienna, a Master of Biotechnology from the University of Agricultural Sciences of Vienna and a MBA from the Webster University, Vienna, Austria.
Corporate Communications Manager
Anja has been communicating science all her professional life. It began with basic and translational science topics at the Max-Delbrück-Center of Molecular Medicine in Berlin-Buch. Being the head of the Public Relations team at the Max-Planck-Institute of Biochemistry in Martinsried near Munich, she was responsible for all external and internal communications, events, a hands-on laboratory, numerous websites and the Corporate Identity of the Institute. Before joining Immatics, Anja was running disease awareness campaigns and communicating clinical trial results at Boehringer Ingelheim.
Anja Heuer holds a Bachelor in Biological Sciences from the University of Konstanz and a Diploma on Journalism from the Berlin School of Journalism.
Associate Director Discovery Group
Arun Satelli joined Immatics in 2015 and leads the early phase research and development of companion diagnostics and biomarker detection strategies to support the preclinical and clinical programs for adoptive cellular therapies (ACT) at Immatics. Since joining Immatics in 2015, Arun has concentrated in the development of an investigational diagnostic device IMADETECTTM in a CLIA/CAP lab setting that can serve as a screening modality to recruit patients for a wide range of ACT trials.
Prior to joining Immatics, Arun worked at MD Anderson Cancer Center, where, he had worked on the development of novel cancer diagnostic approaches for use in early detection as well as therapeutic response determination.
Arun Satelli received his PhD degree in Biomedical sciences from Texas Tech University, Texas, USA and bachelor’s degree in Pharmacy from Osmania University, India.
Managing Director and Chief Medical Officer
As Managing Director and Chief Medical Officer Carsten Reinhardt is responsible for Immunology, Translational Development, Clinical Development and Regulatory Affairs with a focus on T cell receptor identification/engineering and Immatics' bispecific T cell engaging product portfolio.
Carsten Reinhardt joined Immatics Biotechnologies GmbH in October 2009 from Micromet, Inc. (Bethesda, MD), where he was Chief Medical Officer and a member of the management board.
Previously, as International Medical Leader at Hoffmann-La Roche (Basel, Switzerland), Carsten Reinhardt had global responsibility for the development of Herceptin®. Prior to his tenure at Roche, Carsten Reinhardt was Head of Clinical Development at Fresenius Biotech (Munich, Germany).
Carsten Reinhardt has extensive experience in translational development as well as in early and late-stage clinical trial design. Under his leadership multiple biological compounds that address oncology and immunology diseases were progressed from early preclinical development through first-in-man studies towards approvals in the US and Europe. This included the set-up and oversight of pivotal trials leading to the approval of various anti-cancer drugs including Blincyto® in acute lymphoblastic leukemia (ALL), Removab® in solid tumors as well as various sBLA/MAA for Herceptin® in additional indications such as adjuvant breast cancer and gastric cancer.
Prior to joining the pharma and biotech industry, Carsten Reinhardt held various academic medical positions and worked at the University of Tuebingen and Max Planck Institute, Munich to complete his curriculum in Neurology.
Carsten Reinhardt has co-authored more than 40 publications in peer-reviewed journals including Science, Nature Medicine, Lancet, Journal of Clinical Oncology, Cancer Research, and Journal of Experimental Medicine.
Carsten Reinhardt received a Medical Degree in 1994 from the University of Munich, Germany and, in addition, completed a Ph.D. thesis in Cellular Immunology at the Institute of Immunology in Munich, Germany (summa cum laude). He is a member of the American Society of Clinical Oncology, the American Society of Hematology, the Association for Cancer Immunotherapy as well as of the European Society of Medical Oncology, and is Visiting Professor for Pharmaceutical Medicine at the University of Basel.
Senior Director Program Management
Chad Stewart joined Immatics in May 2017 and is responsible for directing the Program Management Team in Houston responsible for delivering the portfolio of T-Cell Programs currently in clinical development.
With over 24 years of industry experience, Chad has held numerous positions in R&D including quality control, clinical data management, clinical pharmacology, and most recently, project management. Chad contributed to the development of the oncology portfolio at GSK where he managed the global development program for Votrient® in renal-cell carcinoma. Chad also managed corporate development projects for Shire and contributed to multiple licensing and M&A deals. Most recently, as a Program Director at Merck, Chad led a team responsible for external clinical collaborations with Merck’s PD-1 inhibitor, Keytruda®.
Chad Stewart holds a Bachelor of Science in Biology, and a Master of Science in Microbiology from Thomas Jefferson University. Chad also holds an MBA from St. Joseph’s University.
Chih-Chiang Tsou, Ph.D.
Principal Scientist Bioinformatics
Chih-Chiang Tsou joined Immatics in February 2016. He is responsible for the bioinformatics activities at Immatics US and a crucial member of the mass spectrometry team where he provides his expertise in the field of computational mass spectrometry and contributes to the advancement of Immatics’ proprietary discovery platform XPRESIDENT®.
Chih-Chiang started his professional career in computational mass spectrometry over a decade ago working as a software engineer in Academia Sinica, a research institute in Taiwan. In 2011 he joined the Nesvizhskii lab at the University of Michigan Ann Arbor campus where he developed DIA-Umpire enabling improved analysis of data-independent mass-spectrometry. Chih-Chiang has published or co-authored several peer-reviewed scientific papers including Nature Methods, Nature Biotechnology, Nature Communications, Proceedings of the National Academy of Sciences, and Molecular and Cellular Proteomics.
Chih-Chiang Tsou holds a Ph. D. in Bioinformatics from the University of Michigan - Ann Arbor. He received his BSc. in Applied Mathematics and MSc. in Computer Science from Providence University in Taiwan.
Associate Director Business Development
Claudia Blattner joined Immatics in September 2015. Her responsibilities include the full range of Immatics’ Business Development and Partnering efforts.
Claudia joined Immatics from Novumed Life Sciences Consulting (now part of EY), where she held a position as consultant focusing on the generation of business insights and the development of strategic growth opportunities for Biotech and Pharma companies.
Claudia previously spent several years at the Scripps Research Institute in La Jolla, CA, USA conducting research aimed at the development of vaccines for HIV.
Claudia Blattner holds a PhD in Biochemistry from the Ludwig-Maximilians University Munich and a Diploma in Chemistry from the Albert-Ludwigs University in Freiburg.
Claudia Wagner joined Immatics in May 2012 and is responsible for T-cell receptor (TCR) discovery and validation on the XCEPTOR® platform. In her department, TCRs recognizing proprietary XPRESIDENT® tumor antigens are isolated from blood products of healthy individuals and patients, followed-by extensive characterization in human cells. Suitable candidates for immunotherapy, either for adoptive cell therapy (ACT) or soluble TCR bispecifics, are tested preclinically for efficacy and safety. Additionally, Claudia is responsible for the refolding unit of peptide-MHC complexes at Immatics.
In 2006, Claudia Wagner obtained her immunology-focused PhD at the Center for Infectious Medicine at Karolinska Institutet, Stockholm, Sweden. She was then trained as postdoctoral fellow in the Department of Immunobiology at Yale University, New Haven, USA prior to joining Immatics. Claudia also holds a master’s degree in Biomedicine from the Karolinska Institutet.
Dieter Rauscher joined Immatics in November 2016 as Director and Head of the global Information Technology team. The IT Team manages Immatics’ IT infrastructure consisting of some 150 servers, more than 3 PB of Storage and keeps the company productive.
Dieter has been awarded 15 times as Microsoft Most Valuable Professional [MVP] for his outstanding expertise and community engagement. He also co-authored several books about Microsoft’s security products.
As IT Manager he spent 12 years with Wellington Partners, a Venture Capital firm in Munich where he was responsible for all IT systems globally. Prior to joining Immatics, he spent several years in IT Consulting for Enterprise Customers focusing on Enterprise Security and Mobility.
Vice President Immunology
Dominik Maurer joined Immatics Biotechnologies GmbH in 2008 the Immunology department.
For 10+ years Dominik has been active in the field of cancer immunotherapy and a leader in human T-cell biology. He invented and developed with his team the Immatics’s T-Cell Receptor (TCR) technology platform XCEPTOR® which is enabling the fast and efficient discovery, engineering and qualification of a large number of high-affinity and high-specificity TCRs that can be used for Adoptive Cell Therapies i.e. ACTengine® and ACTallo® and TCER® - Bispecifics.
Dominik leads a global-acting Immunology department consisting of four divisions responsible for the TCR discovery platform XCEPTOR®, TCER® - Bispecifics preclinical development, cellular & molecular Immunomonitoring, and Product Science of adoptive cell therapies.
Dominik is an inventor of 10+ patents and patent applications and has co-authored 10+ publications in peer-reviewed journals including Nature, Nature Medicine, Science Immunology, Immunity, Lancet Oncology.
Dominik Maurer gained his Ph.D. in Immunology from the University of Tuebingen, Germany.
Associate Director Preclinical Pharmacology & Pharmacokinetics
Frank Schwöbel joined Immatics in October 2017 and is responsible for the management of in vivo and ex vivo studies conducted with contract research organization.
Frank started his career in the pharmaceutical industry as a lab leader in vivo pharmacology at ALTANA Pharma, Konstanz. He then joined the biotech compony NOXXON Pharma in Berlin as a head of pharmacology. There he significantly contributed to the successful preclinical and clinical development of NOX-94 as project leader and senior director. Before joining Immatics, Frank supported the Pharmacology & Toxicology department at CSL Behring, Marburg as a scientist.
Frank Schwöbel holds a Diploma in Biology from the University of Konstanz, Germany, where he also gained his Ph.D. in Biology as a member of the DFG research training group Biochemical Pharmacology. He is a member of the German Society of Pharmacology and Toxicology and the Society of Laboratory Animal Science.
Chief Executive Officer
Harpreet co-founded Immatics in 2000 to translate pioneering scientific discoveries in immunology into highly innovative immunotherapies to impact the lives of cancer patients.
Since the foundation, he has served as Managing Director and Chief Scientific Officer, helping to grow the Company from a start-up to a leading biotech player in the field of immuno-oncology. Harpreet has played a leadership role in raising more than US$200m of venture capital funding over several financing rounds. In 2015, Harpreet became President & CEO of Immatics US, overseeing all operations of Immatics in Houston, Texas to develop next-generation Adoptive Cell Therapies (ACT). He led the team that achieved a $20m CPRIT grant by the State of Texas. Harpreet was awarded "Private Company CEO of the Year" at the Lifestars Awards 2018 (in association with Jefferies), in recognition of his achievements. In 2019, Harpreet became CEO of Immatics Biotechnologies.
Harpreet is the inventor on numerous granted patents and patent applications and co-author of numerous scientific papers published by peer-reviewed journals including Nature, Nature Medicine, Nature Biotechnology, Lancet Oncology. A scholar of Prof. Hans-Georg Rammensee, Harpreet completed his academic studies by gaining a Ph.D. in immunology at the University of Tuebingen, Germany.
Associate Director Target Discovery
Heiko Schuster joined Immatics in 2016 and leads the Target Discovery Unit within the Discovery Department.
The development of novel cancer immunotherapies has been the center of Heiko’s academic and industrial professional life over the last decade. At Immatics, Heiko has led the discovery of cryptic targets and was involved in various aspects of target characterization contributing to the advancement of Immatics’ proprietary XPRESIDENT® platform. Heiko is an inventor on several patents and (co-) authored many publications in the fields of cancer immunology and immunopeptidomics, published in peer-reviewed journals including Nature, Leukemia and PNAS.
Heiko holds a Ph.D. in Biochemistry from the University of Tuebingen.
Jens joined Immatics in April 2007 and heads the Bioinformatics Department which contributes to Immatics’ preclinical and clinical research by providing expertise in data analysis and modelling as well as statistics and machine learning.
Jens introduced quantitative immunopeptidomics to XPRESIDENT® a decade ago. Since then, he and his team have continuously extended XPRESIDENT®’s capabilities with cutting-edge methods from computational mass-spectrometry and next-generation sequencing while enabling ongoing data growth through development of supporting front- and back-end database technologies.
Jens is an inventor on many patents and co-authored publications in the cancer immunology field in prestigious peer-reviewed journals including Nature, Lancet Oncology and Immunological Reviews. He studied computer science (Bioinformatics) at the University of Tuebingen, Germany.
Director Human Resources & Operations
Jessica Mosby joined Immatics in September 2017 and is responsible for providing strategic guidance and leadership for all aspects of human resource functions and establishing a vision and direction for the full complement of core human capital programs, policies and services. This includes providing leadership and direction in the development of human resources and organizational policies that promote maximum effectiveness in the Immatics’ workforce while supporting the Immatics’ mission.
Jessica’s professional background of over 25 years includes working in the fields of Biopharmaceuticals, Higher Education, Group Counseling, Jury Consulting, Mediation and Mass Tort Litigation.
Jessica Mosby has an eclectic educational background in Psychology, Business and Law and most recently earned her doctorate in Organizational Psychology and is currently pursuing her Juris Doctorate with an emphasis in Business and Employment Law.
Jorge M. Rivas,
Associate Director Regulatory Affairs
Jorge M. Rivas joined Immatics in March 2019 as Associate Director or Regulatory Affairs. He is responsible for regulatory compliance of the company’s clinical-stage investigational/therapeutic products in the US. With an academic background and training in Immunology, Internal Medicine, and Chemistry, Jorge has accumulated considerable experience in the fields of T-cell-based cancer immunotherapies and biotherapeutics.
Prior to joining Immatics, Jorge held positions at Bellicum Pharmaceuticals, Covance, and Novum and trained as a post-doctoral fellow at the Institute of Bioscience and Technology (Texas A&M HSC) in Houston, Texas and as an internal medicine resident at St. Joseph’s Hospital and Medical Center in Phoenix, Arizona.
Jorge M. Rivas received his Medical Degree in 1997 from the University of Texas Medical Branch at Galveston. He also completed a Ph.D. in Immunology in 1993 from the University of Texas Health Science at Houston after graduating from the University of Texas at El Paso with a bachelor’s degree in Chemistry. Jorge has co-authored several scientific publications in peer-reviewed journals.
Katja Steinhardt joined Immatics in March 2019 and is responsible for all German HR Topics.
In the last 5 years Katja has worked with Terrabit GmbH, an IT service provider. As the Head of HR, she was responsible for the employees in Reutlingen, Hamburg, Karlsruhe and Ulm. The focus of her role was to establish a companywide career model, to improve the objective setting/review process and to introduce the HR business partner function to the organization. Her previous position at ToolBox Software GmbH was split between the American subsidiary in Minneapolis and the German in Aachen. She was responsible to develop new HR processes and to hire people for technical positions. Furthermore, she was responsible for corporate development at Toolbox, with the main focus on employee development and to improve employee loyalty.
Katja Steinhardt received a bachelor’s degree in business psychology from SRH Riedlingen and is currently enrolled in a master’s program with PFH Göttingen in labor law.
Kerry Sieger joined Immatics in August 2015. As Director QA/QC, she oversees all Quality Assurance and Quality Control activities related to ACT manufacturing and clinical trials. Her duties also include managing the labs’ readiness for all research departments.
Kerry started her career in the lab at Baylor College of Medicine, then switched to industry when she joined Introgen Therapeutics, eventually becoming Quality Control Supervisor there. After a return stint in academia at MD Anderson Cancer Center, Kerry became Quality Assurance Manager at Novum Pharmaceutical Research Services in Houston. There she added knowledge of Good Clinical Practice to her expertise in Good Manufacturing Practice. After six years at Novum, Kerry came to Immatics as Senior Manager QA/QC.
Kerry Sieger holds a Bachelor’s degree in Biological Sciences from the University of Notre Dame and a Master’s degree in Cellular and Molecular Biology from Washington University in St. Louis.
Associate Director CMC
Mamta Kalra joined Immatics in April 2016 and is responsible for manufacturing process development and viral vector-related assay development for ACT programs.
Mamta has extensive experience in the field of basic and applied Immunology that started with her doctoral research in TB vaccine development. She transitioned from Infectious Disease to Cancer Immunology during her postdoctoral years initially studying immunomodulatory factors in HCV-related liver cancer followed by T-cell therapy of EBV-related cancers. She was instrumental in optimizing manufacturing process for virus-specific and CAR-T cells. Her work also included potency testing of products and immune-monitoring for multiple adoptive T-cell therapy trials. Upon joining Immatics as a Sr. Scientist, she led process development for ACTengine program.
Mamta Kalra holds a PhD in Immunology from India and a postdoctoral training in adoptive T-cell therapy from Center for Cell and Gene Therapy at Baylor College of Medicine.
Associate Director Immunology
Martin Hofmann joined Immatics in 2015 and he is responsible for in-house production, purification processes and analytical characterization of bispecific T cell-engaging receptor (TCER®) molecules. He strongly participated in the development of the TCER® molecular scaffold and further established all relevant production and purification processes for different bispecific TCR molecules. In his current role, Martin serves as CMC expert for supporting GMP production of the first TCER® program.
Martin has been working with mono- and multi-specific antibodies since his diploma thesis. After receiving his PhD in 2013 he worked as a research scientist at Synimmune GmbH, a spin-off of the Department of Immunology of the University of Tuebingen. There he participated in GMP-compliant production and analytics of a therapeutic antibody.
Martin Hofmann holds a PhD in Biological Sciences from the University of Tuebingen.
Associate Director Target Validation
Martina Ott joined Immatics in 2014 and leads the Target Validation Unit within the Discovery Department.
Manipulating the immune system to fight diseases has been the focus of Martina’s career. Before joining Immatics, Martina investigated the effects of a novel immunomodulator developed by Teva Pharmaceutical Industries Ltd. to treat multiple sclerosis. At Immatics, Martina has implemented an in-situ hybridization-based target validation platform and was appointed to be head of laboratory in 2015. Over time, she was involved in target discovery and validation for several internal and collaboration projects. Martina is (co-) author of several publications in the fields of neuro- and cancer immunology.
Martina Ott holds a Diploma in Molecular Medicine from the University of Erlangen-Nuremberg and a Ph.D. in Molecular Medicine from the University of Goettingen.
Director EU Regulatory Affairs
Miriam Meyer joined Immatics in September 2009 and is Director and Head of Regulatory Affairs in Europe.
Miriam began her carrier at Hexal AG in Holzkirchen where she started with Regulatory Affairs for classical generic products and later became the regulatory lead for the development of Hexal’s first biosimilar medicinal product. Thereafter, Miriam moved to GPC Biotech GmbH where she gained experience in the field of Regulatory Affairs for small molecules and biological products developed for cancer therapies. Since 2009 Miriam has been working for Immatics and signs responsible for strategic and operational Regulatory Affairs for the entire Immatics product pipeline developed in the EU.
Miriam completed her Ph.D. thesis in Molecular biology in the lab of Axel Ullrich at the Max-Planck-Institute of Biochemistry in Martinsried. She holds a Master of Drug Regulatory Affairs from the University Bonn and a Diploma in food chemistry from the University Kaiserslautern.
Vice President Translational Development
Norbert Hilf is heading the Department of Translational Development responsible for the transition of R&D projects into preclinical and finally clinical first-in-human stage. Further, his department is performing Project Management for internal programs as well as Industry Partnerships and oversees R&D Strategy and Communications, and Biosample Logistics. Norbert is also coordinating the development of Immatics’ global QM systems.
Since he joined Immatics in 2004, he engaged in R&D projects as a science-driven Immunologist. Norbert’s department gained expertise in the development of multi-peptide cancers vaccines, actively personalized immunotherapies, adoptive cellular therapies, and bispecific T-cell receptors - from the preclinical stage up to Phase I clinical trials.
Norbert Hilf studied biochemistry at the University of Tübingen and holds a doctoral degree in Biochemistry / Immunology. For his thesis, he joined Hans-Georg Rammensee’s group and worked on links between innate and adaptive immunity.
Vice President Discovery
Oliver Schoor joined Immatics in 2005 and heads the Discovery Department dedicated to target discovery and validation.
Making use of the immune system to fight cancer has been the guiding theme of Oliver’s career. His initial role with Immatics focused on scientifically and technically strengthening Immatics’ proprietary XPRESIDENT® technology platform, which has been the source of cancer targets for all of Immatics’ therapeutic approaches. Over time, Oliver held several different positions in project and alliance management for internal research programs as well as in the context of collaborations with the pharmaceutical industry and other external partners.
Oliver Schoor holds a Diploma in Biochemistry and a Ph.D. in Immunology from the University of Tübingen.
Managing Director and Chief Business Officer
Rainer Kramer joined Immatics Biotechnologies GmbH in April 2012 from Signature Diagnostics AG where he was member of the Management Board and Chief Business Officer. He is responsible for Immatics’ corporate business development activities, intellectual property and corporate communications.
During his career, he has delivered numerous strategic partnerships and license deals encompassing technology and product deals as well as equity transactions with an aggregate value of more than $3 billion. During the sale of Jerini to Shire in 2008 he was a member of Jerini’s M&A committee and Shire’s appointed principal for the sale of Jerini’s spin out of JPT Peptide Technologies GmbH in 2009. Rainer Kramer has worked in research and business development functions with increasing responsibilities at Amgen Inc., MorphoSys AG, Jerini AG, Shire PLC and Signature Diagnostics AG.
Rainer Kramer holds a Diploma in Molecular Biology from University of Regensburg and a Ph.D. from the Max-Planck-Institute for Neurobiology, Martinsried, Germany.
Director IT, Immatics US
Riky Tran joined Immatics in Oct 2015 and is responsible for all information technology environment through Immatics US – encompassing a wide variety of Governance of policy, resource allocation, and IT protocols.
Prior to joining Immatics, Riky spent 20+ years in information technology. Most recently, Riky served as a vice President of Tradition Bank for 12 years where he has helped the information technology department scoring a 90% satisfactory rating on all federal and state examinations with.
Riky Tran holds a Bachelor of Science in Computer Information Science from Minnesota State University, Mankato (formerly Mankato State University).
Director Translational Development, R&D Strategy and Communications
Sarah Missel joined Immatics in 2011, where she started as Scientist in Immunology and subsequently held several positions leading cross-functional teams in various internal and collaboration projects. Her work as Director Translational Development is focused on R&D strategy and communications, as well as translation of preclinical projects into early phase clinical trials with a current focus on T cell engaging bispecifics (TCER®) and personalized immunotherapies.
Sarah studied Pharmacy at the University of Würzburg and gathered some experience in clinical research at GSK. Her academic research at the Institute of Virology of TU/Helmholtz Centre Munich was focused on therapeutic HIV vaccines and immune monitoring in clinical trials.
Sarah Missel holds a State Exam in Pharmacy and a PhD in Pharmacology/Immunology/Virology from LMU and Helmholtz Centre Munich
Maria Poulada joined Immatics in January 2013. Maria has been leading the Finance department, consisting of, amongst others, finance, controlling, reporting, accounting and taxation on a global level. Currently, she is in maternity leave.
Maria is an experienced finance professional with a demonstrated 12-year history of working in Finance departments of SMEs and listed companies in Athens, prior to joining Immatics. Her expertise lies, amongst others, in the areas of finance, managerial accounting, budgeting and reporting, IFRS, consolidation, systems’ implementations, investments’ valuations, people management.
Maria is a Certified Public Accountant of CPA UK. She holds a Bachelor’s degree in Economics from the University of Piraeus and a Master’s degree in Finance and Banking from the Athens University of Economics and Business. She is currently pursuing a Doctorate in Business Administration from the Business School Netherlands.
Regina Mendrzyk joined Immatics in March 2007 and was involved in the setup and development of Immatics’ highly standardized Immunomonitoring and global PBMC logistics platforms. She led the Immunomonitoring of several global clinical trials. In her current role she leads the Houston-based Immunology department as well as the Immunomonitoring department in Tuebingen. The main focus of the research conducted in both departments is the deep understanding and improvement of all of Immatics’ immunotherapeutics, i.e. the adoptive cellular therapies and the T cell engaging bispecifics (TCER®).
Prior to joining Immatics, Regina pursued intensive studies on the development of therapeutic vaccines targeting Human Papillomaviruses (HPV) during her PhD and gained considerable expertise in immune assays.
Regina Mendrzyk holds a Diploma in Biology from Justus-Liebig University of Gießen and a Ph.D. from the DKFZ Heidelberg.
Associate Director Financial Planning & Analysis
Sebastian Bunk joined Immatics in 2014 where he is responsible for developing a pipeline of bispecific T cell-engaging receptor (TCER®) molecules. His department is dedicated to generating preclinical proof-of-concept for efficacy, safety and manufacturability of novel TCER® programs. He has further responsibility in structure-based optimization of T cell receptors (TCRs) for improving their performance in adoptive cell therapy (ACT).
Under Sebastian’s scientific leadership, Immatics established innovative technology for affinity maturation of TCRs and generation of bispecific TCER® molecules. He is an inventor on 10+ patents related to discovery and engineering of TCRs and bispecific TCER® programs and has co-authored 10+ publications in peer-reviewed journals.
Sebastian obtained his Ph.D. in Biochemical Pharmacology from the University of Konstanz. Prior to joining Immatics, he worked as Manager at Baxter Innovations in Vienna where he led R&D projects related to different biotherapeutics, such as intravenous immunoglobulin.
Director Clinical Operations
Shanna Jackson joined Immatics as the Director of Clinical Operations in April 2019 and leads the team responsible for the planning and execution of clinical trials for the Immatics portfolio (ACTolog, ACTengine, and ACTallo).
Prior to joining Immatics, Shanna served as the Director of Clinical Operations at Lexicon Pharmaceuticals. In addition to her contributions to numerous IND submissions across multiple therapeutic areas, Shanna had the privilege of leading the team responsible for telotristat ethyl (Xermelo®), Lexicon’s first approved product. She was actively involved in the development of the program in an orphan Oncology indication from IND to post-market life-cycle management. Today, she looks forward to the next contribution that will improve patient’s treatment options and quality of life.
Shanna Jackson holds a Bachelor degree in Biomedical Science from Texas A&M University, a Master’s Degree in Business Administration with a specialty in Human Resources, and is a registered nurse.
Associate Director CMC
Sonja Dorner joined Immatics in August 2007. She heads the CMC Peptides Department and is responsible for peptide synthesis and control to supply all R&D departments with peptides needed for the discovery and validation of new targets as well as for the development and manufacturing of new cellular and bispecific therapies.
Since Sonja joined in 2007, she held various positions in the CMC department focused on peptide synthesis and peptide analytics as well as GMP compliant drug product manufacturing. She was part of peptide vaccine pharmaceutical development, manufacturing and control and strongly contributed to actively personalized vaccine trials.
Sonja holds a Bachelor in Chemistry and a Master of Science in Bio- and Process Analytics from the University of Reutlingen.
Chief Scientific Officer,
Steffen Walter joined Immatics Biotechnologies GmbH in 2005 where he became VP Immunology.
For over 15 years he has been active in the field of cancer immunotherapy and a leader in human T-cell biology. In addition to supporting the development of the XPRESIDENT® technology platform, under his leadership, Immatics developed its powerful Immunomonitoring and T-cell receptor (TCR) discovery platforms to support the generation of safe and effective T-cell-based therapeutic modalities.
In 2015, Steffen Walter established operations of Immatics US, Inc. in Houston, Texas in close collaboration with MD Anderson Cancer Center (MDACC) as Chief Scientific Officer to develop next-generation adoptive cell therapies (ACT). He contributed significantly to raising the necessary funding including a $20m CPRIT grant by the State of Texas.
Steffen Walter leads a team that is responsible for Product Science, Process Development, Manufacturing, Quality Control and Program Management for Immatics’ cell therapy programs.
Steffen Walter is an inventor on numerous patents and patent applications and has co-authored more than 30 publications in prestigious peer-reviewed journals including Nature Medicine, Cell Reports, Lancet Oncology, Brain and Blood.
Steffen Walter gained his Ph.D. in Immunology from the University of Tuebingen, Germany.
Chief Medical Officer,
As Chief Medical Officer of Immatics US Inc. Stephen Eck leads the clinical development of Immatics Adoptive Cell Therapy programs in Houston.
Stephen Eck joined Immatics US in April 2018 from Astellas. Stephen Eck previously served as VP Oncology Medical Sciences at Astellas Pharma Global Development managing a portfolio of assets which included enzalutamide (Xtandi), erlotinib (Tarceva) and gilteritinib.
Stephen Eck is a Hematologist and Oncologist with more than 25 years of experience in academic and industrial biomedical research. He began his professional career at Monsanto in cancer target discovery and later joined the University of Pennsylvania, where he was the Anne B. Young Assistant Professor of Cancer Research and the Director of the Cancer Gene Therapy Program. He subsequently held leadership roles in drug development at Pfizer, as VP Translational Medicine and Molecular Profiling, and at Lilly, as VP Translational Medicine, Pharmacology and Pharmacogenomics, prior to joining Astellas.
Stephen Eck has authored numerous publications in basic and clinical research and public policy. He is a fellow of the American Association for the Advancement of Science and Chairman of the Personalized Medicine Coalition (Washington DC). He serves on the Board of Directors of Luminex Corporation (Austin, TX), on the Board of Directors of the Central Pennsylvania Clinic (Belleville, PA), and the External Advisory Committee of the University of Pennsylvania Orphan Diseases Program (Philadelphia). He is a Trustee of the Keck Graduate Institute (Claremont, CA).
Stephen Eck received an BA (chemistry) from Kalamazoo College, an MS and a PhD (chemistry) from Harvard University and an MD from the University of Mississippi with Residency (Internal Medicine) and Fellowship (Hematology & Oncology) training at the University of Michigan.
Managing Director and Chief Financial Officer
Thomas Ulmer joined Immatics Biotechnologies GmbH in April 2018 from the Merck Group, where he was Chief Financial Officer of the Allergopharma Business Unit. During his tenure with Allergopharma he was the key architect for defining and implementing the business strategy towards geographic expansion and updating the product portfolio.
Thomas Ulmer began his professional career with Merck in 2004 and has held a number of roles, including Head of Business Planning & Analysis and previously Head of Planning, Forecasting & Resource Allocation for the Merck Group. During this time, he acted as a sparring partner to the Group Executive Board and helped develop and implement the new company strategy which included a major transformation. He has also been Chief Financial Officer for Australia/ New Zealand and Financial Controller for Merck’s global generics business when it was sold to Mylan and he played a leading role of the integration of the business and built up an OTC business unit in Australia for which he received the company’s innovation award.
Thomas Ulmer is a Certified Practising Accountant of CPA Australia and holds an MBA of Justus-Liebig-University of Giessen.
Chief Technology Officer
Toni Weinschenk co-founded Immatics Biotechnologies GmbH in 2000.
Over the past two decades, Toni Weinschenk has been active in the field of cancer immunology. He oversees all of Immatics’ target discovery and companion diagnostics activities..
He is the inventor of Immatics’ proprietary XPRESIDENT® technology platform, which is enabling the discovery and validation of the most comprehensive array of cancer targets derived from both, cell surface and intracellular antigens. Toni Weinschenk has earned the reputation as the world’s leading expert in ultra-sensitive, quantitative and high-throughput mass spectrometry of HLA ligands, a technology that is integral to XPRESIDENT®. Targets identified by XPRESIDENT® have proven to be important assets in several licensing deals with partners from the pharma industry and academia.
Toni Weinschenk is an inventor on many patents and co-authored publications in the cancer immunology field in prestigious peer-reviewed journals including Nature, Nature Medicine, Nature Immunology, Immunological Reviews and Cell Report.
Toni Weinschenk studied biochemistry at the University of Tuebingen, Germany and at the Max-Planck-Institute, Munich, Germany.
Director Intellectual Property
Wolfgang Flasche joined Immatics in 2006. He is heading the IP department and responsible for all IP related topics, including patents, trademarks, trade secrets, agreements and know-how all around the world. He is representing Immatics before the European Patent Office and the USPTO. Furthermore, he is managing all of Immatics’ alliances with pharma partners.
Wolfgang started in the IP department of Bayer in Leverkusen right out of his PhD. After a position as a Head of IP at a smaller Biotech company in Munich he joined Immatics.
Wolfgang Flasche holds a Diploma from the Philipps Universität in Marburg and a PhD in bio-organic chemistry from the Humboldt Universität Berlin. He is a European Patent Attorney.
Director Translational Development
In his current role, Yannick Bulliard is responsible for the translational development of the ACTallo® platform, Immatics’ off-the-shelf T cell therapy, and ACTengine® IMA204, based on autologous, engineered TCR-T cells.
Yannick joined Immatics in June 2016 to establish the Department of Product Science. Prior to Immatics, Dr. Bulliard was a Program Lead at Amgen, Inc. for the preclinical development of bispecific antagonists to checkpoint inhibitors.
Yannick Bulliard obtained his Ph.D. from the Ecole Polytechnique Federale de Lausanne, Switzerland and pursued his career with a postdoctoral fellowship at the Novartis Institute for Biomedical Research, where he studied the mechanism of action of diverse checkpoint regulators in immuno-oncology.
Associate Director CMC
Zoe Coughlin joined Immatics in July 2015 and is responsible for leading the clinical manufacturing of multiple adoptive cell therapy programs for various solid cancers. In this role, she has helped guide all Immatics’ active clinical trials through pre-clinical development, IND approval, and patient treatment.
Zoe has more than 10 years of experience in GMP manufacturing of cell and gene therapy products. Before joining Immatics, Zoe was a Senior Clinical Cell Therapy Specialist at M.D. Anderson Cancer Center involved in the manufacture and administration of multiple cell therapy products including the Sleeping Beauty transposon-based CAR-T program.
Zoe Coughlin holds a bachelor’s degree in Microbiology from Texas A&M University and a bachelor’s degree in Clinical Laboratory Science from The University of Texas M.D. Anderson Cancer Center. Zoe also holds a master’s degree in Clinical Practice Management from Texas Tech University and maintains an MLS (ASCP)CM certification.